II. Amendments to the Claims

Claims 1-6 (Cancelled).

7. (Currently Amended) ~~The~~ A glycopeptide ~~of claim 1 which is a compound~~ of formula II:



(II)

wherein:

R^3 is -OH;

R^5 is hydrogen;

R^{19} is hydrogen;

~~R^{20} is R^a-Y-R^b-$(Z)_x$-R^f, -C(O)R^f, or -C(O)-R^a-Y-R^b-$(Z)_x$; and~~

~~R^a, Y, R^b, Z, x, R^f, R^3, and R^5 have any of the values defined in claim 1;~~

R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-Y-R^b-(Z)_x$ or $-CH_2-CH(OH)CH(OH)CH_2-R^{17}$;

R^{17} is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocyclic;

Y is selected from the group consisting of oxygen, sulfur, $-S-S-$, $-NR^c-$, $-S(O)-$, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, $-OC(O)-$, $-NR^cSO_2-$, $-C(O)NR^c-$, $-C(O)O-$, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, $-OC(O)O-$, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$, $-C(=O)-$ and $-NR^cSO_2NR^c-$;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

R^b is selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; and

x is 1 or 2;

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof.

Claims 8-12 (Canceled).

13. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of ~~claim 1~~ Claim 7.

14. (Currently Amended) The pharmaceutical composition of claim 13, ~~which~~ wherein the composition further comprises a cyclodextrin.

Claim 15 (Canceled).

16. (Original) A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide of claim 7.

17. (Original) A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of claim 13.

18. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-R^{17}$ and R^{17} is alkyl.

19. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-R^{17}$ and R^{17} is aryl.

20. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-Y-R^b-(Z)_x$ and Y is $-NH-$.

21. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-Y-R^b-(Z)_x$ and Y is oxygen.

22. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-Y-R^b-(Z)_x$ and Y is sulfur.

23. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2-CH(OH)CH(OH)CH_2-Y-R^b-(Z)_x$ and R^b is alkylene.

24. (New) The glycopeptide of Claim 7, wherein R^{20} is $-CH_2\ CH(OH)CH(OH)CH_2-Y-R^b-(Z)_x$ and Z is hydrogen.

25. (New) The glycopeptide of Claim 7, wherein R^{20} is a group of the formula:



26. (New) The glycopeptide of Claim 7, wherein R^{20} is a group of the formula:



27. (New) The glycopeptide of Claim 7, wherein R^{20} is a group of the formula:



28. (New) The glycopeptide of Claim 7, wherein R^{20} is a group of the formula: